CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC)
Publication
, Conference
Heist, RS; Wang, XF; Hodgson, L; Otterson, GA; Stinchcombe, T; Vokes, EE; Socinski, MA
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2012
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2012
Volume
30
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Heist, R. S., Wang, X. F., Hodgson, L., Otterson, G. A., Stinchcombe, T., Vokes, E. E., & Socinski, M. A. (2012). CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 30). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
Heist, Rebecca Suk, Xiaofei F. Wang, Lydia Hodgson, Gregory Alan Otterson, Tom Stinchcombe, Everett E. Vokes, and Mark A. Socinski. “CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
Heist RS, Wang XF, Hodgson L, Otterson GA, Stinchcombe T, Vokes EE, et al. CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.
Heist, Rebecca Suk, et al. “CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 15, AMER SOC CLINICAL ONCOLOGY, 2012.
Heist RS, Wang XF, Hodgson L, Otterson GA, Stinchcombe T, Vokes EE, Socinski MA. CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2012
Volume
30
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences